



## Investor News 2016

The news contents can be obtained from our website [www.investor.bayer.com](http://www.investor.bayer.com)

Date	News
December 13, 2016	<p><b>Monsanto Shareowners Approve Merger with Bayer</b></p> <ul style="list-style-type: none"> <li>- Key Milestone in Merger to Create a Global Leader in Agriculture</li> <li>- Close of Transaction Expected by the End of 2017</li> </ul>
December 12, 2016	<p><b>Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing</b></p> <ul style="list-style-type: none"> <li>- BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols</li> <li>- BlueRock Therapeutics' vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions</li> </ul>
December 07, 2016	<p>Bayer strengthens U.S. animal health portfolio: <b>Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter Into Agreement for Purchase of U.S. Cydectin® Product Portfolio</b></p>
November 16, 2016	<p>NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA <b>Bayer successfully places EUR 4 billion of mandatory convertible notes</b></p>
November 15, 2016	<p>NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA <b>Bayer to issue mandatory convertible notes</b></p>
November 14, 2016	<p>Not intended for U.S. and UK Media - New Study Presented at American Heart Association (AHA) Scientific Sessions 2016: <b>Bayer's Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention</b></p> <ul style="list-style-type: none"> <li>- PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population</li> <li>- Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine</li> </ul>
November 07, 2016	<p>Not intended for U.S. and UK Media - American Heart Association (AHA) Scientific Sessions 2016: <b>PIONEER AF-PCI Study with Bayer's Xarelto® Accepted as Late-Breaking Clinical Trial Presentation at AHA 2016</b></p>
November 07, 2016	<p>Not intended for U.S. and UK Media <b>Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer</b></p> <ul style="list-style-type: none"> <li>- Regulatory submissions in the U.S., Japan and Europe were completed based on data from the Phase III RESORCE study, in which regorafenib demonstrated statistically significant improvement in overall survival</li> <li>- Currently there are no approved therapies for the treatment of unresectable hepatocellular carcinoma (HCC) in the second-line setting</li> </ul>

Date	News
October 26, 2016	<p>Third quarter of 2016:  <b>Bayer shows strong performance - Acquisition of Monsanto agreed</b></p> <ul style="list-style-type: none"> <li>- Group sales increase by 2.3 percent (Fx &amp; portfolio adj. 3.5 percent) to EUR 11,262 million</li> <li>- Pharmaceuticals sustains very good business development</li> <li>- Moderate increase in sales at Consumer Health</li> <li>- Crop Science successful in a persistently difficult market environment</li> <li>- EBITDA before special items up by 6.0 percent to EUR 2,682 million</li> <li>- Net income improves by 18.8 percent to EUR 1,187 million</li> <li>- Core earnings per share increase by 2.4 percent to EUR 1.73</li> <li>- Forecast for core earnings per share raised</li> <li>- Agreed acquisition of Monsanto creates a global leader in agriculture</li> </ul>
October 05, 2016	<p><b>Bayer completes sale of Bayer Garden and Bayer Advanced businesses to SBM</b></p>
October 04, 2016	<p>Not intended for U.S. and UK Media  <b>Bayer receives green light for new five-year contraceptive in the EU</b></p> <ul style="list-style-type: none"> <li>- New low dose levonorgestrel-releasing intrauterine system will be named "Kyleena™"</li> <li>- Introduction in Europe is scheduled to start in January 2017</li> </ul>
September 29, 2016	<p>Not intended for U.S. and UK Media  <b>Bayer comments on article in The British Medical Journal (BMJ) regarding Xarelto®</b></p>
September 28, 2016	<p>Not intended for U.S. and UK Media  <b>Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure</b></p>
September 20, 2016	<p>"Meet Management" investor conference:  <b>Bayer sets ambitious growth and earnings aspirations</b></p> <ul style="list-style-type: none"> <li>- Further sales and earnings growth pursued in all businesses</li> <li>- Combined peak annual sales potential of recently launched pharmaceutical products raised to over EUR 10 billion</li> <li>- Six further product candidates in the Pharmaceuticals pipeline have combined peak sales potential of at least EUR 6 billion</li> <li>- Strong brands driving business at Consumer Health</li> <li>- Above-market sales growth and substantial margin increases expected at Crop Science following the closing of the agreed acquisition of Monsanto</li> </ul>
September 19, 2016	<p>Not intended for U.S. and UK Media  <b>FDA approves new five-year-contraceptive of Bayer</b></p>
September 14, 2016	<p><b>Bayer and Monsanto to Create a Global Leader in Agriculture</b></p> <ul style="list-style-type: none"> <li>- Realizes a shared vision of integrated agricultural offerings, delivering enhanced solutions for growers and creates a leading innovation engine for the next generation of farming</li> <li>- USD 128 per share in all-cash transaction, represents 44 percent premium to Monsanto shareholders and an aggregate value of USD 66 billion</li> <li>- Significant value creation with expected annual synergies of approximately USD 1.5 billion after year three; plus additional synergies from integrated solutions in future years</li> <li>- Bayer shareholders expected to benefit from accretion to core EPS in the first full year after closing and double-digit percentage accretion in the third full year</li> <li>- Committed to retaining strong presence in the U.S. with the combined business' global Seeds &amp; Traits and North American commercial headquarters in St. Louis</li> </ul>

Date	News
September 07, 2016	<p><b>Bayer's commitment to innovation and sustainability will help shape the future of farming</b></p> <ul style="list-style-type: none"> <li>- Strong innovation pipeline will help solve key agricultural challenges</li> <li>- Sustained high R&amp;D investment level of about 10 percent of sales confirmed</li> <li>- EUR 2.5 billion capital expenditure program from 2017 to 2020</li> <li>- Strong commitment to sustainability also supported by investments in Digital Farming, ForwardFarming and Smallholder Farming</li> </ul>
September 06, 2016	<p><b>Negotiations regarding Monsanto acquisition advance</b></p>
August 29, 2016	<p>Not intended for U.S. and UK Media - ESC Congress 2016:</p> <p><b>Real-World Data from Multiple Countries Continue to Reaffirm Positive Benefit-Risk Profile of Bayer's Xarelto® in Everyday Clinical Practice</b></p> <ul style="list-style-type: none"> <li>- Late-breaking XAPASS study in patients with non-valvular atrial fibrillation (AF) in Japan reaffirms low rates of both stroke and major bleeding with Xarelto in routine clinical practice, consistent with Phase III J-ROCKET AF</li> <li>- Ongoing post-authorisation safety study based on Registers in Sweden confirms low rates of intracranial bleeding with Xarelto vs. warfarin in line with ROCKET AF</li> <li>- Additional real-world data presented from REVISIT-US study, which investigated rivaroxaban, apixaban and dabigatran, each compared with warfarin, in patients with non-valvular AF</li> <li>- Real-world data on Xarelto provide additional insights beyond Phase III clinical trials and better represent the diverse patient populations treated in routine clinical practice</li> </ul>
August 22, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer's Xarelto® Accepted for Presentation at ESC Congress 2016</b></p> <ul style="list-style-type: none"> <li>- New real-world data will provide further insights on the use of Xarelto across diverse patient populations seen in everyday clinical practice</li> <li>- Results from the real-world observational XAPASS study of Xarelto in everyday patients with non-valvular AF in Japan will be presented during a Late-Breaking Registries Session</li> <li>- New real-world data from REVISIT-US investigating rivaroxaban, apixaban and dabigatran, each compared with warfarin, in patients with non-valvular AF will be presented during a Poster Session</li> </ul>
July 27, 2016	<p>Second quarter of 2016:</p> <p><b>Bayer raises sales and earnings</b></p> <ul style="list-style-type: none"> <li>- Group sales increase by 2.3 percent (Fx &amp; portfolio adj.) to EUR 11,833 million</li> <li>- Pharmaceuticals continues strong growth trend</li> <li>- Consumer Health increases sales</li> <li>- Crop Science business holds steady in a continually difficult market environment</li> <li>- EBITDA before special items up 5.7 percent to EUR 3,054 million</li> <li>- Net income improves by 18.6 percent to EUR 1,380 million</li> <li>- Core earnings per share increase by 4.0 percent to EUR 2.07</li> <li>- Group forecast raised</li> </ul>
July 19, 2016	<p><b>Bayer Comments on Monsanto's Statement Regarding its Increased All-cash Offer</b></p>
July 14, 2016	<p><b>Bayer increases Monsanto offer and provides certainty on financing and regulatory matters</b></p>
June 28, 2016	<p>Not intended for U.S. and UK Media: Phase III data at ESMO 18th World Congress on Gastrointestinal Cancer (WCGC):</p> <p><b>Bayer's Regorafenib Significantly Improves Overall Survival in Patients with Unresectable Liver Cancer</b></p> <ul style="list-style-type: none"> <li>- Initial results from Phase III trial RESORCE to be presented as Late-Breaking Abstract in oral abstract session at WCGC</li> <li>- Median overall survival was 10.6 months for patients treated with regorafenib plus best supportive care versus 7.8 months in the group treated with placebo plus best supportive care</li> </ul>

Date	News
June 03, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer and Orion Expand Clinical Development Program With New Phase III Study ARASENS for BAY-1841788 (ODM-201) in Prostate Cancer</b></p> <ul style="list-style-type: none"> <li>- Phase III study ARASENS to be initiated in metastatic hormone sensitive prostate cancer assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel</li> <li>- Start of patient enrolment expected towards the end of 2016</li> </ul>
June 01, 2016	<p>Not intended for U.S. and UK Media - New Phase III Study for Stivarga® (Regorafenib):</p> <p><b>Bayer collaborates with U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) to Investigate Stivarga® (Regorafenib) as Additional Adjuvant Therapy in Colon Cancer</b></p> <ul style="list-style-type: none"> <li>- Study will include patients with Stage IIIB and IIIC colon cancer who have undergone complete surgical resection of primary tumor and received standard adjuvant chemotherapy</li> <li>- Indication-seeking trial will be conducted by NSABP with the support from Bayer</li> </ul>
May 24, 2016	<p><b>Bayer Comments on Monsanto's Statement Regarding Proposed Transaction</b></p>
May 23, 2016	<p>Innovation Powerhouse to Deliver Integrated Solutions for the Next Generation of Farming:</p> <p><b>Bayer Offers to Acquire Monsanto to Create a Global Leader in Agriculture</b></p>
May 19, 2016	<p><b>Bayer and SBM Développement sign agreement for sale of Bayer Garden and Bayer Advanced businesses</b></p>
May 19, 2016	<p><b>Bayer Confirms Preliminary Discussion Regarding Acquisition of Monsanto</b></p>
May 12, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias</b></p>
May 04, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival</b></p>
April 29, 2016	<p>Dr. Marijn Dekkers at the Annual Stockholders' Meeting of Bayer AG:</p> <p><b>"Innovation is our future"</b></p> <ul style="list-style-type: none"> <li>- 2015 was a very successful year for Bayer both strategically and operationally</li> <li>- Dividend increase to EUR 2.50 per share proposed</li> <li>- Employees to share in the company's success through total bonuses of around EUR 1.1 billion</li> <li>- Good start to fiscal 2016</li> </ul>
April 26, 2016	<p>Interim report for the first quarter of 2016:</p> <p><b>Bayer off to a successful start in 2016</b></p> <ul style="list-style-type: none"> <li>- Substantial sales growth at Pharmaceuticals</li> <li>- Earnings expand in all segments</li> <li>- Group sales increase to EUR 11,941 million (plus 0.5 percent / Fx &amp; portfolio adj. plus 3.2 percent)</li> <li>- EBITDA before special items advances by 15.7 percent to EUR 3,404 million</li> <li>- EBIT up 20.1 percent to EUR 2,335 million</li> <li>- Net income grows by 13.3 percent to EUR 1,511 million</li> <li>- Core earnings per share up 13.9 percent to EUR 2.37</li> <li>- Outlook for 2016 confirmed</li> </ul>
April 25, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Patent Term for Rivaroxaban Extended in US</b></p>
April 21, 2016	<p><b>Bayer deposits 10 million Covestro shares in Bayer Pension Trust e. V.</b></p>

Date	News
April 18, 2016	<p>Not intended for U.S. and UK Media - 12th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:</p> <p><b>New Data Reaffirm Positive Benefit-Risk Balance of Bayer's Xarelto® in Patients with Atrial Fibrillation in Daily Clinical Practice</b></p> <ul style="list-style-type: none"> <li>- Insights from nearly 23,000 patients with atrial fibrillation on the prevention of stroke and incidence of intracranial haemorrhage with Xarelto vs. warfarin</li> <li>- Results confirm the efficacy and safety profile of Xarelto as determined in pivotal Phase III ROCKET AF and other real-world studies</li> </ul>
March 29, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Receives Approval for Kovaltry® for the Treatment of Hemophilia A in Japan</b></p>
March 29, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Receives Approval for Xofigo® in Japan</b></p> <p>Marketing authorization granted for the treatment of castration-resistant prostate cancer patients with bone metastases</p>
March 24, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer and Regeneron To Jointly Develop Novel Combination Therapy for Eye Diseases</b></p>
March 17, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Receives FDA Approval for Kovaltry® for the Treatment of Children and Adults with Hemophilia A</b></p>
February 25, 2016	<p>Fiscal 2015:</p> <p><b>Another record year for Bayer</b></p> <ul style="list-style-type: none"> <li>- Focus on the Life Sciences following the successful stock market flotation of Covestro</li> <li>- Substantial sales and earnings increases at HealthCare</li> <li>- Good business development at CropScience despite a weaker market environment</li> <li>- Covestro posts strong earnings improvement</li> <li>- Group sales increase to EUR 46,324 million (plus 12.1 percent / Fx &amp; portfolio adj. plus 2.7 percent)</li> <li>- EBITDA before special items advances by 18.2 percent to EUR 10,266 million</li> <li>- EBIT improves by 15.8 percent to EUR 6,250 million</li> <li>- Net income increases 20.0 percent to EUR 4,110 million</li> <li>- Core earnings per share up 16.0 percent to EUR 6.83</li> <li>- Forecast for 2016: further growth in sales and earnings</li> </ul>
February 24, 2016	<p><b>Bayer proposes increased dividend for 2015 of EUR 2.50 per share</b></p> <p>Total dividend payout rises 11.1 percent to EUR 2,067 million</p>
February 24, 2016	<p>Change at the top effective May 1, 2016:</p> <p><b>Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG</b></p>
February 22, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>Bayer Receives EU Approval of Kovaltry® for Treatment of Hemophilia A</b></p>
February 05, 2016	<p>Not intended for U.S. and UK Media</p> <p><b>EMA Reaffirms Positive Benefit-Risk Balance of Bayer's Xarelto® for Stroke Prevention in Patients with Atrial Fibrillation</b></p>
January 05, 2016	<p><b>Bayer closes on divestiture of Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for around EUR 1 billion</b></p> <p>Transaction includes blood glucose monitoring systems and lancing devices for people with diabetes</p>